Protein Structure Initiative

WikiDoc Resources for Protein Structure Initiative
Articles
Most recent articles on Protein Structure Initiative Most cited articles on Protein Structure Initiative Review articles on Protein Structure Initiative Articles on Protein Structure Initiative in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Protein Structure Initiative Images of Protein Structure Initiative Photos of Protein Structure Initiative Podcasts & MP3s on Protein Structure Initiative Videos on Protein Structure Initiative
Evidence Based Medicine
Cochrane Collaboration on Protein Structure Initiative Bandolier on Protein Structure Initiative TRIP on Protein Structure Initiative
Clinical Trials
Ongoing Trials on Protein Structure Initiative at Clinical Trials.gov Trial results on Protein Structure Initiative Clinical Trials on Protein Structure Initiative at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Protein Structure Initiative NICE Guidance on Protein Structure Initiative NHS PRODIGY Guidance FDA on Protein Structure Initiative CDC on Protein Structure Initiative
Books
Books on Protein Structure Initiative
News
Protein Structure Initiative in the news Be alerted to news on Protein Structure Initiative News trends on Protein Structure Initiative
Commentary
Blogs on Protein Structure Initiative
Definitions
Definitions of Protein Structure Initiative
Patient Resources / Community
Patient resources on Protein Structure Initiative Discussion groups on Protein Structure Initiative Patient Handouts on Protein Structure Initiative Directions to Hospitals Treating Protein Structure Initiative Risk calculators and risk factors for Protein Structure Initiative
Healthcare Provider Resources
Symptoms of Protein Structure Initiative Causes & Risk Factors for Protein Structure Initiative Diagnostic studies for Protein Structure Initiative Treatment of Protein Structure Initiative
Continuing Medical Education (CME)
CME Programs on Protein Structure Initiative
International
Protein Structure Initiative en Espanol Protein Structure Initiative en Francais
Business
Protein Structure Initiative in the Marketplace Patents on Protein Structure Initiative
Experimental / Informatics
List of terms related to Protein Structure Initiative

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

PSI logo

The Protein Structure Initiative (PSI) is a 10-year, $764 million effort begun in 2000 to accelerate discovery in structural genomics. Funded by the U.S. National Institute of General Medical Sciences (NIGMS), its aim is to reduce the cost and time required to determine three-dimensional protein structures. Over a dozen research centers are supported in the PSI for work in building and maintaining high-throughput structural genomics pipelines, developing computational protein structure prediction methods, and organizing and disseminating information generated by the PSI.

The project has been organized into two separate phases. The first phase of the Protein Structure Initiative (PSI-1) spanned from 2000 to 2005, and was dedicated to demonstrating the feasibility of high-throughput structure determination, solving unique protein structures, and preparing for a subsequent production phase. The second phase, PSI-2, has focused on implementing the high-throughput structure determination methods developed in PSI-1, as well as homology modeling and addressing bottlenecks like modeling membrane proteins.

Phase 1

The first phase of the Protein Structure Initiative (PSI-1) lasted from June 2000 until September 2005, and had a budget of $270 million funded primarily by NIGMS with support from the National Institute of Allergy and Infectious Diseases. PSI-1 saw the establishment of nine pilot centers focusing on structural genomics studies of a range of organisms, including Arabidopsis thaliana, Caenorhabditis elegans and Mycobacterium tuberculosis. During this five-year period over 1,100 protein structures were determined, over 700 of which were classified as "unique" due to their < 30% sequence similarity with other known protein structures.

The primary goal of PSI-1, to develop methods to streamline the structure determination process, resulted in an array of technical advances. Several methods developed during PSI-1 enhanced expression of recombinant proteins in systems like Escherichia coli, Pichia pastoris and insect cell lines. New streamlined approaches to cell cloning, expression and protein purification were also introduced, in which robotics and software platforms were integrated into the protein production pipeline to minimize required manpower, increase speed, and lower costs.

Phase 2

The goal of the second phase of the Protein Structure Initiative (PSI-2) is to use methods introduced in PSI-1 to determine a large number of proteins and continue development in streamlining the structural genomics pipeline. Scheduled to operate between July 2005 and June 2010, PSI-2 has a five-year budget of $325 million provided by NIGMS with support from the National Center for Research Resources. As of November 1, 2008, the Protein Structure Initiative has solved over 3400 protein structures; over 1,900 of these are unique.

Bar chart showing growth over time of protein structures deposited by the Protein Structure Initiative into the Protein Data Bank

The number of sponsored research centers grew to 14 during PSI-2. The new centers participating in PSI-2 include four specialized centers: Accelerated Technologies Center for Gene to 3D Structure, the Center for High-Throughput Structural Biology (a branch of the Structural Genomics of Pathogenic Protozoa Consortium taking that institution's place), the Center for Structures of Membrane Proteins, and the New York Consortium on Membrane Protein Structure. Two homology modeling centers, the Joint Center for Molecular Modeling and New Methods for High-Resolution Comparative Modeling were also added, as well as two resource centers, the PSI Materials Repository and the PSI Structural Genomics Knowledgebase (SGKB). The TB Structural Genomics Consortium was removed from the roster of supported research centers in the transition from PSI-1 to PSI-2.

Line chart depicting structures deposited in the PDB by large-scale PSI centers over time

Originally launched in February 2008, the SGKB is a free resource that provides information on protein sequence and keyword searching, as well as modules describing target selection, experimental protocols, structure models, functional annotation, metrics on overall progress, and updates on structure determination technology. Like the PDB, it is directed by Dr. Helen M. Berman and hosted at Rutgers University.

The PSI Materials Repository, established in 2006 at the Harvard Institute of Proteomics, stores and ships PSI-generated plasmid clones. Clones are annotated and stored in the Plasmid Information Database (PlasmID) upon submission. As of November 16, 2008 there are almost 10,000 PSI-generated plasmid clones available through PlasmID in addition to over 100,000 clones generated from non-PSI sources. The PSI Materials Repository has a five year budget of $5.4 million, and is under the direction of Dr. Joshua LaBaer.

Impact

PDB structure 2p69, one of the protein structures solved by the New York SGX Research Center for Structural Genomics, a large scale PSI center. This human phosphatase is involved in vitamin B₆ (shown in stick diagram) metabolism .

As of January 2006, about two thirds of worldwide structural genomics (SG) output was made by PSI centers. Of these PSI contributions over 20% represented new Pfam families, compared to the non-SG average of 5%. Pfam families represent structurally distinct groups of proteins as predicted from sequenced genomes. Not targeting homologs of known structure was accomplished by using sequence comparison tools like BLAST and PSI-BLAST. Like the difference in novelty as determined by discovery of new Pfam families, the PSI also discovered more SCOP folds and superfamilies than non-SG efforts. In 2006, 16% of structures solved by the PSI represented new SCOP folds and superfamilies, while the non-SG average was 4%. Solving such novel structures reflects increased coverage of protein fold space, one of the PSI's main goals. Determining the structure a novel protein allows homology modeling to more accurately predict the fold of other proteins in the same structural family.

While most of the structures solved by the four large-scale PSI centers lack functional annotation, many of the remaining PSI centers determine structures for proteins with known biological function. The TB Structural Genomics Consortium, for example, focuses exclusively on functionally characterized proteins. During its term in PSI-1, it deposited structures for over 70 unique proteins from Mycobacterium tuberculosis, which represented more than than 35% of total unique M. tuberculosis structures solved through 2007. In following with its biomedical theme to increase coverage of phosphotomes, the NYSGXRC has determined structures for about 10% of all human phosphatases.

The PSI consortia have provided the overwhelming majority of targets for the Critical Assessment of Techniques for Protein Structure Prediction (CASP), a community-wide, biannual experiment to determine the state and progress of protein structure prediction.

Criticism

The PSI has received notable criticism from the structural biology community. Among these charges is that the main product of the PSI -- PDB files of proteins' atomic coordinates as determined by X-ray crystallography or NMR spectroscopy -- are not useful enough to biologists to justify the project's $764 million cost. The structures solved by the PSI often do not yield significant functional information on the protein. For example, while the anti-leukemia drug Gleevec was being developed, only the open structure of its target enzyme, Bcr-Abl tyrosine kinase, was available. Since only the kinase's closed form binds Gleevec, the open structure was of no use to Novartis while designing the drug. Critics also note that money currently spent on the PSI could have otherwise funded what they consider worthier causes:

The $60 million a year in public money that is being spent - I would say, wasted - on the PSI is enough to fund approximately 100-200 individual investigator-initiated research grants. These hypothesis-driven proposals are the lifeblood of the scientific enterprise, and as I have discussed recently in other columns, they are being sucked dry by, among other things, an increasing trend to fund large initiatives at their expense. That $60 million a year would raise the payline at a typical NIH institute by about 6 percentile points, enough to make a huge difference to peer review and to the continuance of a lot of important science.

— Gregory Petsko, PhD

External links

PSI-Nature Structural Genomics Knowledgebase Statistics, news and research advances related to the PSI
PSI Material Repository Centralized storage, maintenance and distribution of plasmid clones produced by PSI researchers